All In Biotech

Drug Trial Radar · NCT05355402

A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and/or With Severe Hypertriglyceridemia

A Randomized, Double-blind, Placebo-Controlled, Phase 2b Study of ISIS 678354 in Patients With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and/or With Severe Hypertriglyceridemia

Last checked: Nov 20, 2026Latest source record: Apr 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 154 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

154

Actual

Start

May 9, 2022

Primary completion

Mar 22, 2023

Study completion Dec 21, 2023

Sponsor

Lead sponsor
Ionis Pharmaceuticals, Inc.Ionis Pharmaceuticals (IONS)
Sponsor type
Industry
First posted
May 2, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study was to evaluate the effect of olezarsen on percent change in fasting triglyceride (TG) levels compared to placebo at Months 6 and 12 and the proportion of participants who achieve different thresholds in fasting TG. Other objectives were to evaluate the effect of olezarsen on percent change in fasting apolipoprotein C-III (apoC-III), very low-density lipoprotein cholesterol (VLDL-C), remnant cholesterol, non-high-density lipoprotein cholesterol (non-HDL-C), HDL-C, total cholesterol (TC), apolipoprotein B (apoB), low-density lipoprotein cholesterol (LDL-C), and apolipoprotein A-1 (apoA-1).

Conditions

  • Hypertriglyceridemia
  • Atherosclerotic Cardiovascular Disease
  • Severe Hypertriglyceridemia

Interventions

  • OlezarsenDrug

    SC injection.

  • PlaceboDrug

    SC injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change From Baseline in Fasting TG at Month 6Time frame: Baseline, Month 6

Locations

24 sites in 2 countries. Site status is shown where the registry gives one.

  • Clinical Trials Research

    Lincoln, California

  • Catalina Research Institute, LLC

    Montclair, California

  • Excel Medical Clinical Trials, LLC

    Boca Raton, Florida

  • De La Cruz Research Center

    Miami, Florida

  • Suncoast Clinical Research, Inc.

    New Port Richey, Florida

  • Research Physicians Network Alliance

    Winter Park, Florida

  • IACT Health

    Columbus, Georgia

  • Evanston Premier Healthcare Research

    Evanston, Illinois

  • Clinical Investigation Specialist

    Gurnee, Illinois

  • West Broadway Clinic

    Council Bluffs, Iowa

  • Louisville Metabolic and Atherosclerosis Research Center (L-MARC)

    Louisville, Kentucky

  • Aa Mrc, Llc

    Flint, Michigan

  • Clinical Research of South Nevada

    Las Vegas, Nevada

  • Palm Research Center, Inc.

    Las Vegas, Nevada

  • Green and Seidner Family Practice Associates

    Lansdale, Pennsylvania

  • Main Street Physicians Care Waterway

    Little River, South Carolina

  • Health Concepts

    Rapid City, South Dakota

  • Tennessee Center for Clinical Trials

    Tullahoma, Tennessee

  • Southern Endocrinology Associates

    Mesquite, Texas

  • Manassas Clinical Research Center

    Manassas, Virginia

  • York Clinical Research LLC

    Norfolk, Virginia

  • Clinique des Maladies Lipidiques de Quebec Inc.

    Québec, Canada

  • Bluewater Clinical Research Group Inc

    Sarnia, Ontario, Canada

  • Ecogene-21

    Chicoutimi, Quebec, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.